Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the KnowHow program, a 10-week digital intervention designed to promote healthy eating and activity behaviors among families with young children. The study focuses on assessing how feasible and acceptable this program is for parents of preschool-aged children, including how well families engage with the program and their intentions to continue its practices. The intervention targets health behavior improvements in early childhood by providing parent education on mindful parenting, nutrition, and physical literacy. The KnowHow program includes three main components a custom mobile app delivering educational content and activities, virtual group discussions held via Zoom, and child-centered support materials mailed to families. The app is organized into five modules containing lessons, activities, and assessments focused on mindful parenting, healthy eating, and physical activity. Two groups are studied one receives the 10-week intervention, and a delayed control group does not receive the program during the study period but gains access afterward. Participants will be assessed at baseline week 0 and after the 10-week intervention post-test for several outcomes including recruitment, retention, usability, acceptability, digital engagement, and intention to sustain behaviors. Behavioral outcomes such as mindful parenting, parent-child feeding practices, and physical activity parenting practices are measured before and after the intervention. Parent self-efficacy and behavioral skills are also evaluated. The total study duration for participants is 10 weeks, with no additional assessments for the control group after the intervention period.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of IMP1734, a PARP1 selective inhibitor, in people with advanced solid tumors. This study includes patients with breast cancer, metastatic prostate cancer, ovarian cancer, and other solid tumors who have previously received certain treatments. The goal is to find an optimal dose for future clinical development by studying how the drug affects the body and how the body processes it. The study has two parts Part 1 involves gradually increasing doses of IMP1734 given as a daily oral tablet to identify the highest safe dose or maximum achievable dose. This includes testing the drug alone and in combination with other treatments for specific cancers like metastatic prostate, ovarian, and breast cancer. Part 2 focuses on refining the dose to find the best amount for future studies. Treatment can last up to three years after the first dose. Participants will be monitored closely with assessments of side effects, blood tests to study drug levels and effects, and evaluations of tumor response using standard criteria. Safety monitoring continues up to 30 days after the last dose. Researchers measure how well the drug is tolerated and its impact on the cancer over time. The total participation may extend up to three years, with ongoing evaluations during this period.
Actively Recruiting
Researchers are conducting a master protocol study to evaluate the long-term safety and efficacy of the drug pirtobrutinib in patients who have completed previous clinical studies involving this medication. This study includes participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma and aims to monitor their health over an extended period. The master protocol organizes individual study-specific appendices ISAs representing participants from earlier originator studies. Participants continue to receive pirtobrutinib as they did in their original clinical study, with the drug administered orally. The study allows these individuals to keep taking the treatment or to continue with follow-up visits under this master protocol framework. The study is designed to gather safety and survival data over many years. During the study, participants will be closely monitored for any serious treatment-related side effects, with assessments focused on adverse events occurring from the first dose until shortly after the last dose or when starting a new anticancer therapy. Researchers will also track overall survival for up to 93 months. This long-term follow-up ensures comprehensive safety and health evaluations throughout the participants involvement, which may last several years.
Actively Recruiting
This research aims to assess the long-term safety and effectiveness of pirtobrutinib in people who have previously been treated for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma. It is a Phase 4 study involving participants who completed an earlier study called LOXO-BTK-18001. The study invites these participants to continue their assigned treatment or follow-up in this extension study. Participants will continue receiving pirtobrutinib, which is taken orally, as they did in the original study. This study serves as an individual-study appendix under the master protocol J2N-MC-JZNY. There are no new treatment groups participants maintain the therapy they were assigned before. During the study, participants will be monitored for serious treatment-related side effects, including tracking any grade 3 or higher adverse events occurring from the first dose through 30 days after the last dose or until starting a new cancer therapy. Researchers will also observe overall survival up to 93 months from enrollment in the original study. Participants will have regular follow-up visits to assess their health and treatment safety over the long term.
Actively Recruiting
Researchers are evaluating MCLA-158, a bispecific antibody targeting EGFR and LGR5, in patients with advanced or metastatic solid tumors, including metastatic colorectal cancer mCRC and head and neck squamous cell carcinoma HNSCC. This Phase 12 open-label, multi-center study aims to find the recommended dose for further testing and assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of MCLA-158 alone or combined with other treatments. The study has two parts an initial dose escalation phase that determined the recommended Phase II dose RP2D of MCLA-158, and an expansion phase where this dose is given every two weeks by intravenous infusion to patients with selected solid tumors. The expansion includes single-agent cohorts and combination cohorts where MCLA-158 is tested with pembrolizumab, FOLFIRI chemotherapy, or FOLFOX chemotherapy. Different doses and a subcutaneous formulation are also evaluated in some groups. Participants receive treatment cycles lasting 28 days with infusions on Day 1 and Day 15. Researchers monitor safety through adverse events and dose-limiting toxicities, tumor response, drug levels in blood, and other clinical and laboratory assessments over months to years. The study includes regular evaluations with imaging, laboratory tests, and heart function monitoring, with follow-up extending up to three years to assess response duration, progression-free survival, and overall survival.
Actively Recruiting
Researchers are studying NX-5948, an oral drug, in adults with relapsed or refractory B-cell malignancies, including various lymphomas and leukemias such as Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, and others. This Phase 1a1b open-label trial aims to assess the safety, tolerability, and anti-cancer activity of NX-5948 in patients who have received prior treatments and have limited options. The study includes multiple cohorts focusing on different types of B-cell cancers and specific patient characteristics. The study has two main parts Phase 1a dose escalation to determine the maximum tolerated dose and recommended dose for further study, followed by Phase 1b safety expansion and cohort expansion to evaluate the drugs anti-tumor activity at selected doses across various patient groups. Participants receive oral NX-5948 at different dose levels, with some groups randomized to compare doses. The treatment targets a range of B-cell malignancies, including those affecting the central nervous system. Participants are closely monitored throughout the study for dose-limiting toxicities, adverse events, and anti-tumor responses using established criteria. Assessments include measuring overall response rates, pharmacokinetics, pharmacodynamics, and survival outcomes over periods lasting up to several years. The study involves regular visits for safety and efficacy evaluations, and participants organ and bone marrow functions are monitored to ensure suitability for treatment.
Actively Recruiting
Researchers are studying the long-term safety of pirtobrutinib in people who have previously been treated for chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This study welcomes participants who completed the earlier LOXO-BTK-20020 trial to continue receiving the study drug or attend follow-up visits. The study is a Phase 4 treatment trial sponsored by Eli Lilly and Company. Participants will receive pirtobrutinib orally every 4 weeks. There is also a group receiving idelalisib orally. This study is designed as a parallel, non-randomized trial and is expected to last approximately 5 years, allowing continued access to treatment or follow-up for participants from the previous study. During the study, participants will be monitored for treatment-emergent adverse events of grade 3 or higher from the first dose through 30 days after the last dose or start of new anticancer therapy. Researchers will also track overall survival from enrollment in the original study until death from any cause, up to about 93 months. Participants will have regular visits over the study period for safety and health assessments.
Actively Recruiting
Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effects of NDI-219216 in patients with advanced solid tumors, including those with or without microsatellite instability and deficient mismatch repair. This early phase 12 study aims to understand how NDI-219216 affects tumor size, its side effects, and its impact on the body. The trial is sponsored by Nimbus Wadjet, Inc. and includes patients whose tumors are advanced and have not responded to standard treatments or for whom no standard options exist. The study involves three parts Part A focuses on dose escalation where patients receive increasing doses of NDI-219216 daily in 28-day cycles to find the best dose. Part B randomizes patients into up to three dose groups determined from Part A to further evaluate the treatment daily in 28-day cycles. Part C enrolls patients with specific tumor biomarkers dMMRMSI-H using the optimal dose from Part B. Participants take NDI-219216 orally every day throughout these cycles. Participants visit the clinic six times during the first 28-day cycle, twice in the second cycle, and then monthly for checkups and tests while on treatment. After finishing treatment, there is an end-of-treatment visit and a follow-up that can be done by phone. Patients keep a diary to track their tablet intake and any symptoms. Researchers assess safety by monitoring side effects, tumor response using imaging criteria, and measure drug levels in the blood at scheduled times during the first treatment cycle. The study may last up to 17-18 months depending on the part of the trial.
Actively Recruiting
Healthy Volunteer
Researchers are studying iron requirements in a representative group of adult men and premenopausal women living in the United States. This research aims to improve dietary iron guidelines by using the iron isotope dilution technique to better reflect the needs of the US population. The study involves adults aged 18 to 50 who have either participated in a previous isotope study or are willing to take part in a new one. Participants will receive a stable iron isotope and then be monitored over a 12-week period. Blood samples will be collected every 4 weeks to measure the iron isotope composition. This helps researchers understand how the body absorbs and uses iron. During the study, participants will undergo blood collection and provide consent for storing blood samples for future research. Researchers will track the iron isotope levels in the blood as the main outcome. Participants must follow study rules such as avoiding iron supplements, tobacco smoking, and blood donation during the study. The entire process takes about 12 weeks, with regular blood tests and monitoring.
1-10 of 20
1